
==== Front
Sports Med Health Sci
Sports Med Health Sci
Sports Medicine and Health Science
2666-3376
Chengdu Sport University

S2666-3376(23)00024-0
10.1016/j.smhs.2023.03.004
Review
More than a key—the pathological roles of SARS-CoV-2 spike protein in COVID-19 related cardiac injury
Lin Zhiqiang zlin@mmri.edu

Masonic Medical Research Institute, 2150 Bleecker Street, Utica, NY, 13501, USA
30 3 2023
9 2024
30 3 2023
6 3 209220
11 1 2023
13 3 2023
22 3 2023
© 2023 Chengdu Sport University. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.
2023
Chengdu Sport University
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Cardiac injury is common in hospitalized coronavirus disease 2019 (COVID-19) patients and cardiac abnormalities have been observed in a significant number of recovered COVID-19 patients, portending long-term health issues for millions of infected individuals. To better understand how Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, CoV-2 for short) damages the heart, it is critical to fully comprehend the biology of CoV-2 encoded proteins, each of which may play multiple pathological roles. For example, CoV-2 spike glycoprotein (CoV-2-S) not only engages angiotensin converting enzyme II (ACE2) to mediate virus infection but also directly activates immune responses. In this work, the goal is to review the known pathological roles of CoV-2-S in the cardiovascular system, thereby shedding lights on the pathogenesis of COVID-19 related cardiac injury.

Keywords

COVID-19
Spike protein
Cardiovascular disease
Immune responses
==== Body
pmcList of abbreviations:

COVID-19 coronavirus disease 2019

CoV coronavirus

SARS-CoV-2 (CoV-2) Severe Acute Respiratory Syndrome Coronavirus 2

CoV-2-S Severe Acute Respiratory Syndrome Coronavirus 2 spike protein

ARDS acute respiratory distress syndrome

PRR pattern recognition receptor

ACE2 angiotensin converting enzyme II

SAg superantigen

APC alternative complement activation pathway

DAMPs danger associated molecular patterns

MI myocardial infarction

TMPRSS2 transmembrane serine proteinase 2

Introduction

In 2003, severe acute respiratory syndrome coronavirus (SARS-CoV) caused SARS epidemic in Asia1; in 2012, the first case of Middle East Respiratory Syndrome (MERS) was reported,2 marking the outbreak of MERS epidemic in the Arabian Peninsula. Since 2019, the coronavirus disease 2019 (COVID-19) pandemic has put the whole world in danger. Behind all these two epidemics and one pandemic is one group of viruses, the coronavirus (CoVs) family.

CoVs are enveloped RNA viruses. Until now, 7 CoVs have been known to infect humans, including HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, SARS-CoV, MERS-CoV, and SARS-CoV-2.3 The first four CoVs only cause “common cold” or minor upper/lower respiratory diseases.4,5 In contrast, SARS-CoV, MERS-CoV, and SARS-CoV-2 are deadly viruses that cause acute respiratory distress syndrome (ARDS) and death.3 SARS-CoV-2 is the pathogen of COVID-19, and its genome shares an 82% identity with that of SARS-CoV.3 In addition to high genome sequence similarity, SARS-CoV-2 and SARS-CoV share similar pathogenesis patterns, and so most of the knowledge about SARS-CoV can be referenced to understand the pathogenesis of SARS-CoV-2.

Since the outbreak of COVID-19, scientists and front-line health workers have been trying their best to understand this syndrome. As a result of their endeavors, the death rate of COVID-19 has been greatly reduced and a series of excellent reviews about the pathology of COVID-19 have been published,6, 7, 8, 9, 10 which are invaluable for those readers who want to understand more about COVID-19.

Over the course of the COVID-19 pandemic, cardiovascular injury is common in hospitalized COVID-19 patients and associated with increased mortality,11 and persistent cardiac injury is also common among COVID-19 survivors.12 To treat acute and post-acute COVID-19 manifestations, significant efforts need to be put forth to dissect the pathogenesis of COVID-19-related cardiovascular diseases. Here I reviewed the molecular mechanism of how SARS-CoV-2 damages the cardiovascular system, with a focus on elucidating the multiple pathological roles of SARS-CoV-2 spike protein in COVID-19-associated cardiovascular diseases.

The pathophysiology of myocardial dysfunction in COVID-19

Contagious infection of SARS-CoV-2 (CoV-2) may result in severe illness and bring overwhelming stress to the circulatory system. Therefore, it is anticipated that COVID-19 patients with underlying cardiovascular conditions are prone to have severe adverse outcomes, which has been confirmed by two independent retrospective cohort studies11,13 and one recently published prospective longitudinal study.14 These studies also singled out cardiac injury as one independent risk factor associated with a higher mortality rate in hospitalized COVID-19 patients. Additionally, independent cardiac magnetic resonance imaging studies clearly showed cardiomegaly in athletic COVID-19 patients.7,15,16 In this review, by combing through the clinical observations and pathological findings, I highlighted four reasons that may cause myocardial injury and cardiac dysfunction in COVID-19 patients (Fig. 1).Fig. 1 Comparison of normal and COVID-19 stressed myocardium. A. Normal myocardium. B. COVID-19 stressed myocardium with edema. Patients with severe COVID-19 symptoms are at high risk of developing heart injury. Their heart muscle layers are facing multifaceted stresses, including but not limited to hypoxia stress caused by acute respiratory distress syndrome (ARDS) and coronary artery micro-thrombosis, imbalanced neurohormones (e.g. Ang II), cytokine storm stress, and SARS-CoV-2 infection-caused CM loss.

Fig. 1

CoV-2 infection causes hypoxemia stress

For each beat, the heart needs a large amount of oxygen to generate power for pumping blood throughout the whole body. Therefore, low blood oxygen saturation (known as hypoxemia) will cause hypoxia stress to the heart and reduce heart function. Severe COVID-19 patients usually have acute lung injury, which may progress to ARDS and severe hypoxemia17 which causes cardiac damage. Serologic cardiac troponin T (cTnT) level is a standard diagnose marker for cardiac injury18 and COVID-19 patients with elevated cTnT levels also had severe respiratory dysfunction,11 therefore, bolstering the causal relationship between hypoxemia and cardiac injury. Besides ARDS-induced hypoxemia, COVID-19-caused coronary microthrombi also contribute to myocardial injury,19 and electrocardiograms (ECGs) of COVID-19 patients with cardiac injury displayed abnormalities that are compatible with myocardial ischemia, such as T-wave depression and inversion, ST-segment depression and pathological Q-waves.13,19

One COVID-19 case study clearly demonstrated a causal relationship between hypoxemia and cardiac dysfunction. In this study, a 69-year-old male patient had worsening dyspnea before being hospitalized, and he quickly developed end-stage heart failure (% Ejection Fraction ​= ​25%) and severe hypoxemia after being registered in the hospital. After receiving Extracorporeal membrane oxygenation (ECMO) treatment that provides respiratory support, the patient's left ventricle function progressively recovered to a normal range on day 5,20 thus suggesting that hypoxemia is one of the primary reasons causing cardiac injury in hospitalized COVID-19 patients.

CoV-2 infection induces neurohumoral stress

The renin-angiotensin system (RAS) plays central roles in maintaining blood pressure homeostasis.21 In this system, renin is an aspartic protease that cleaves liver-synthesized angiotensiongen to produce angiotensin (an inactive decapeptide hormone), which is further converted to angiotensin II (AngII, an active octapeptide vasoconstrictive hormone) by angiotensin converting enzyme (ACE). As a homologue of ACE, ACE2 converts AngII to Ang 1–7. AngII has pleiotropic biological effects, such as increasing vessel contraction, activating renal sympathetic nerve cells to release catecholamine hormones, promoting the generation of reactive oxygen species (ROS), and enhancing inflammatory responses.22 On the contrary Ang1-7 mediates anti-inflammatory and vasodilatory effects.23

Acute stress-induced cardiomyopathy, also known as Takotsubo cardiomyopathy, is a reversible heart failure syndrome that resembles acute myocardial infarction (MI). In these patients, the coronary arteries are not obstructed, and characteristic transient ballooning of the apical and mid-ventricular myocardium is presented.24,25 This symptom is triggered by emotional or physical stress, and clinical manifestations include myocardial macrophage inflammatory infiltration,25 increase of systemic pro-inflammatory cytokines and circulating catecholamine levels.26

CoV-2 uses ACE2 as its receptor to infect human cells,27 which harms the human body by killing two birds with one stone: on one hand, the wide expression of ACE2 makes the virus easy to spread; on the other hand, engaging and inactivating ACE2 potentially predisposes the patients to neurohumoral stresses by increasing AngII level.28 In a COVID-19 case study, a 43-year-old female patient had oppressive chest pain, dyspnea, and oxygen desaturation. Lab test results showed elevated cTnT, NT-proBNP, and C-reactive protein, indicating the occurrence of cardiac injury. Echocardiography data showed mild left ventricular systolic dysfunction and anterolateral ventricle wall hypokinesis. No ventricle dilation and pericardial effusion were detected. The patient was diagnosed with acute virus-negative lymphocytic myocarditis, and her cardiac systolic function fully recovered after receiving anti-virus medicine treatment.29 This report suggests that dramatic mental or physical stresses caused by CoV-2 may elicit Takotsubo cardiomyopathy in COVID-19 patients.

SARS-CoV-2 infection induces septic stress

Sepsis is a systemic inflammatory response to severe and acute pathogen infection.30 The pathophysiology of septic stress involves complicated interactions between pathogens and the host innate immune system that recognizes pathogens through pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide (LPS) in bacteria, and DNA or RNA in viruses. The battle between pathogens and host cells generates pro-inflammatory cytokines and danger-associated molecular patterns (DAMPs).31 PAMPs and DAMPs can be recognized by host cell pattern recognition receptors (PRRs), which are specialized signaling proteins capable of initiating innate immune responses to curtail pathogens' spread.32 In an infected tissue, like a domino reaction, the DAMPs released by damaged cells bind to PRRs localized on healthy cells and elicit the production of more pro-inflammatory cytokines and even lead to the generation of reactive oxygen and nitrogen species to further damage the tissue.33

In severe COVID-19 patients, CoV-2 infection causes tremendous damage to the lung34,35 and also leads to endotoxemia by disrupting the integrity of the gastro-intestinal barrier.36 Elevated levels of pro-inflammatory cytokines and increased neutrophil to lymphocytes ratio are two common features in these patients,37 indicating the high chance of septic stress. Septic stress-induced cardiovascular dysfunction is associated with a high mortality rate in sepsis patients.38 It is well-known that septic stress/shock causes myocardial dysfunction by affecting the hemodynamics, blood coagulation, vascular permeability, and cardiomyocyte (CM) contraction.39 The early phase of septic stress is characterized by high cardiac output and low peripheral vascular resistance, and the late phase comprises hypotension, poor peripheral perfusion, and low cardiac output.39 In the sepsis-stressed myocardium, pro-inflammatory cytokines cause endothelial dysfunction and cardiac vascular leakage, followed by a series of harmful events, such as myocardial edema40 and neutrophils infiltration.41 Meanwhile, pro-inflammation cytokines and DAMPs directly bind to their receptors on the CMs to induce apoptosis or dysfunction.42 All these detrimental septic insults together hinder proper myocardium function.

CoV-2 infection leads to viral myocarditis

The aforementioned pathological insults, such as hypoxia stress, neurohumoral stress, and sepsis stress, all can lead to myocarditis, a cardiac inflammatory disease defined by inflammatory infiltrates and non-ischemic myocardial injury. Based on the nature of cardiac inflammation, myocarditis is categorized as viral infection-induced myocarditis and nonviral myocarditis.43

Recently, two independent clinical studies demonstrated that myocardial injury was frequent not only in severely ill COVID-19 patients but also in critically ill non-COVID-19 patients, suggesting that cardiac involvement is not a specific feature of COVID-19.44,45 On top of these clinical observations, post-mortem pathological studies suggest that microthrombi19 is one of the primary causes of myocardial injury, lending additional support to the notion that nonviral myocarditis is the predominant form of cardiac injury in severely ill COVID-19 patients.

Although rare, CoV-2 does infect the heart and causes acute viral myocarditis, at a rate of 0.2%–0.4% among hospitalized COVID-19 patients.46 In these CoV-2 viral myocarditis patients, CoV-2 antigens and RNA were detected in the CMs47, 48, 49 and cardiac interstitial cells,20 confirming that viral myocarditis is one of the causes of COVID-19-associated heart diseases.

In summary, this section described four possible stresses leading to cardiac dysfunction. Although these stresses were discussed separately, it is important to keep in mind that they may happen simultaneously in severely ill COVID-19 patients. Since CMs are the basic cardiac functional units and are adversely affected by COVID-19 stresses, in the next section, I will focus on discussing the possible molecular mechanisms that underly CM damage in COVID-19.

The molecular mechanisms leading to CM injury in COVID-19

The heart contains multiple cell types including CMs, endothelial cells, fibroblasts, neuron cells, and immune cells, and all of these cell types are under stress in the COVID-19 heart. The dysfunction of different cardiac cells may all contribute to COVID-19-related heart injury, which has been nicely outlined in a recent review by Nishiga et al.50 In this section, I will focus on summarizing the possible cellular and molecular mechanisms that lead to CM injury (Fig. 2).Fig. 2 Pathological insults that damage the cardiomyocytes

(CMs) in COVID-19 patients. The CMs are the functional units of the heart, and their loss or dysfunction is the root of cardiac injury. Under homeostasis condition, the CMs are well-supplied with oxygen and their behavior is oscillated by catecholamine hormones. In the myocardium stressed by COVID-19, the CMs are short of oxygen (A) and become insensitive to catecholamines (B). Additionally, circulating pro-inflammatory cytokines or danger associated molecular patterns (DAMPs) damage the CMs by activating their innate immune responses (C). In the worst scenario, SARS-CoV-2 directly infects and destroys CMs (D).

Fig. 2

Hypoxia stress damages the CMs

As mentioned above, hypoxemia is a common feature of severely ill COVID-19 patients.17 Long-time hypoxemia is detrimental and causes cardiac dysfunction.51 On the cellular level, mitochondria respiration generates ATP for the CMs, whose synchronized and constant beating powers the heart. Under the shortage of oxygen supply, the CMs switch to anaerobic glycolysis and generate ATP by turning glucose into lactate. Accumulation of lactate in the CMs increases cellular osmotic gradients, which in turn causes CM edema or apoptosis.52,53 Shortage of oxygen also causes the mitochondria to ROS,54 a spectrum of highly active chemicals that damage cell membranes, DNA, organelles, and induce apoptosis.55 In summary, the CMs can temporarily handle the hypoxia stress, but prolonged hypoxia will lead to CM dysfunction and death (Fig. 2A).

β-adrenergic receptor desensitization impairs CM function

The heart beating rate is established by the Sinoatrial Node (SAN), a cluster of specialized pacemaker CMs localized in the right atrium.56 By influencing the SAN cells, the sympathetic and parasympathetic nerves increase and decrease heart rate, respectively. On the molecular level, the beating rhythm of pacemaker cells is controlled by the hyperpolarization-activated, cyclic nucleotide–gated channels (HCNs) that are responsible for the hyperpolarization-activated current (If).57 Catecholamines are neurotransmitters synthesized by sympathetic neurons and chromaffin cells in the adrenal medulla. Catecholamine molecules, such as epinephrine, norepinephrine, and dopamine, signal the CMs to increase heart rate and contractility. On the CM surface, epinephrine activates β-adrenergic receptors (β-AR) to promote the synthesis of cyclic nucleotides (e.g., cAMP). cAMP in turn initiates signal cascades to increase calcium release58 and If current,59,60 which boosts the heart muscle contractility and pacemaker cell beating rate, respectively (Fig. 2B).

The CMs have evolved a desensitization mechanism to avoid continuous activation of β-AR signaling. Overactivation of β-AR desensitizes the β-AR by inducing β-AR phosphorylation and internalization.58 Because CoV-2 infection can potentially increase the adrenergic tone by engaging ACE2 and by inducing neurohumoral stress, it is likely that the desensitization of β-AR partially accounts for cardiac dysfunction in COVID-19 patients.

DAMPs and cytokines/chemokines activate CM innate immune responses

CoV-2 infection can cause massive lung tissue damage,34 which provokes the release of DAMPs, such as HMGB1, DNA, cell debris, mitochondria, etc, and these DAMPs can potentially be brought to the heart through the circulatory system. Under homeostasis conditions, the CMs express low levels of Toll like receptors (TLRs), a family of pattern recognition receptors (PRRs) that recognize DAMPs. Under disease conditions, such as ischemia and hypertension, the CMs increase TLRs expression61 and therefore become vulnerable to DAMPs molecules, which bind TLRs and elicit signal cascades that promote the production of pro-inflammatory cytokines, and even cause cell death (Fig. 2C). For example, activation of TLR4 is detrimental to the heart, because TLR4 and its downstream kinases promote cytokine genes expression,62 and may also cause pyroptosis,63 a caspase-1 dependent cell death process characterized by cell membrane leakage and release of DAMPs.64 On the contrary, loss of TLR4 is beneficial and protects the heart against lipopolysaccharide (a bacteria-derived toxin) stress.65

CoV-2 infection also causes pro-inflammatory cytokine storm, and the pro-inflammatory cytokines have multiple adverse effects that directly or indirectly cause CM apoptosis and dysfunction. In the heart, the CMs are supported by a fine-tuned microenvironment: oxygen and nutrients are delivered through capillary vessels; sympathetic and parasympathetic nerves provide connections between the CMs and the other parts of the body; residential innate immunes cells guard the CMs against pathogens invasion. The increase of pro-inflammatory cytokines disrupts this microenvironment by interfering with the function of endothelial cells, nerve cells, and innate immune cells. For instance, IL-1β promotes coagulation66 and vessel permeability67; TNFα signals sympathetic nerves to increase the inotropic tone68; IL-17 helps recruit inflammatory neutrophils into the myocardium.69

Pro-inflammatory cytokines also directly change CMs behavior through the cytokine receptors expressed on CM surface.70 Once bound and activated by the pro-inflammatory cytokines, these receptors initiate maladaptive gene expression programs that lead to CM apoptosis, hypertrophy, and dysfunction. In COVID-19 patients, multiple numbers of pro-inflammatory cytokines are known to elevate to form a cytokine storm that stresses the internal organs, including the heart. These up-regulated pro-inflammatory cytokines include IL-6, IL-1β, IL-2, IL-8, IL-17, G-CSF, GM-CSF, IP10, MCP1 and MIP1α,8 many of which are detrimental to the heart. For a better understanding of which cytokines might get involved in COVID-19 cardiac injury, the cellular and molecular effects of the listed pro-inflammatory cytokines were summarized in Table 1.Table 1 The cellular and molecular effects of cytokines elevated in severe COVID-19 patientsa.

Table 1Name	Function in immune system	Effects on the heart and CMs	Clinical trials	
IL-1b	Promote the activity of the innate immune cells.	Promotes ER stress-induced apoptosis.72	Summarized in a recent excellent article.76	
Required for TH17 ​cells differentiation and maintenance.71	Reduces L-type Ca2+ current.73	
	Increases diastolic SR Ca2+ leak.74	
	Promotes cytoskeleton rearrangement and mitochondrial alterations.75	
IL-6	Has broad effects on immune cells and nonimmune cells.	Loss of IL-6 attenuates cardiac inflammation.78,79	Summarized in a recent excellent article.82	
Has context-dependent pro- and anti-inflammatory properties.77	Protects CMs against acute oxidative stress.80 Decreases CM contractility.81	
	Promotes cytoskeleton rearrangement and mitochondrial alterations.75	
IL-8	Recruits and activates neutrophils in inflammatory regions.83	Increases adhesion of neutrophils to CMs in vitro.85 Promotes cytoskeleton rearrangement and mitochondrial alterations.75	Phase I, HuMax-IL8, the monoclone antibody of IL-8, safe for patients with solid tumor.86	
May regulate angiogenesis, tumorigenesis and fibrosis.84	
IL-17	Regulates the expansion and recruitment of neutrophils.	Increases CM apoptosis.87	Secukinumab, the monoclone antibody of IL-17, effective for psoriasis.88	
Promotes the expression of cytokines and anti-microbial genes in nonimmune cells, such as fibroblasts and endothelial cells.69	
GCSF	Important for proliferation and differentiation of haematopoietic cells; Regulates the proliferation and function of Tregs.89	Attenuates isoproterenol induced cardiac hypertrophy.90	Recombinant GCSF therapy decreases left ventricle systolic function.92	
Increases CM hypertrophy in vitro. Increases angiogenesis and decrease fibrosis in a murine MI model.91	
GMCSF (CSF2)	Similar with GCSF.	Helps recruit leukocytes into injured hearts. Loss of GMCSF protects MI injured hearts from rupture.93	No significant adverse effects, but failed to improve survival of sepsis patients.95	
Priming cardiac inflammation in a murine Kawasaki disease model.94	
IP10 (CXCL10)	Induces chemotaxis, apoptosis.	Overexpression of IP10 results in less cardiac damage and better cardiac function in coxsackievirus induced myocarditis model.97	Phase II, Anti-IP-10 antibody is safe but not effective for ulcerative colitis.98,99	
Inhibits cell growth and angiogenesis.96	
MCP1 (CCL2)	Regulates migration and infiltration of monocytes/macrophages.100	Loss of MCP1 attenuates MI-induced cardiac remodeling.101,102	Propagermanium is clinically used CCL2/CCR signaling inhibitor.103	
MIPa (CCL3)	Regulates CD8+ T Cell function and migration.104	Loss of MIPa mitigates cardiomyopathy in a murine Chagasic disease model.106	Not available.	
Required for recruiting neutrophils to virus infected tissue.105	
IL-2	Required for Treg cell differentiation, survival, and function.107	IL-2 indirectly causes heart depression.108	Summarized in an excellent article.107	
a , abbreviations used in this table. IL, interleukin; TH17, T helper type 17 ​cells, characterized by production of IL-17; Treg, regulatory T lymphocytes; ER, endoplasmic reticulum; SR, sarcoplasmic reticulum; GCSF, granulocyte colony-stimulating factor; GMCSF, granulocyte-macrophage colony-stimulating factor; IP10, Interferon gamma-induced protein 10, also known as C-X-C motif chemokine ligand 10; MCP1, monocyte chemoattractant protein-1, also known as Chemokine (CC-motif) ligand 2 (CCL2); MIPa, macrophage inflammatory factor 1a, also known as CCL3; MI, myocardial infarction.

SARS-CoV-2 infects and damages CMs

The CoV-2 life cycle includes seven crucial steps: attachment, entering host cells, uncoating, gene expression, replication, assembly, and release. The first two steps are mediated by CoV-2 spike glycoprotein (CoV-2-S) and its host receptor ACE2, therefore ACE2 expression pattern determines CoV-2 tissue tropism.109 Protruding out of the virus membrane, CoV-2-S latches to host cells through ACE2.21 After attaching to host cells via CoV-2-S/ACE2 interaction, CoV-2 invades the host cells through either cell membrane fusion pathway or clathrin-mediated endocytosis pathway.110

In the past three years, accumulating data have confirmed that CoV-2 infects both CMs and cardiac interstitial cells,20,111, 112, 113, 114 and CoV-2 infection of CMs have been recapitulated in both animal models and cell culture systems. For example, intranasal delivery of CoV-2 to hamsters caused cardiac inflammation,115,116 and CoV-2 virions were detected in CMs including the pacemaker cells.116,117 In vitro, CoV-2 efficiently infects hiPSC-derived CMs (hiPSC-CMs)49,116,118, 119, 120; however, it has very low infection efficiency on cardiac pericytes,121 hiPSC-derived fibroblast,49,118 and hiPSC-derived endothelial cells.122 After successful infection, CoV-2 harms the CMs in a plethora of different ways, such as inducing the formation of syncytia,123 breaking down the contractile machinery,120 impairing electrical functions,119 and eventually resulting in cell death117 (Fig. 2D). Furthermore, whole genome sequencing data from several independent groups all show that CoV-2 infection of hiPSC-CMs induces robust innate immune responses.49,116,118, 119, 120,124 For understanding more details about the mechanisms of how CoV-2 damages CMs, please refer to a recently published review by Qian group.125

The pathological roles of CoV-2-S in COVID-19

To better understand how CoV-2 damages the heart, it is critical to fully comprehend the biology of CoV-2 encoded proteins, each of which may have multiple pathological roles. CoV-2 genome encodes 13 functional protein-coding genes, including four structural genes: spike surface glycoprotein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N); two polyprotein genes ORF1a, ORF1ab; and 7 accessary protein genes: ORFs 3a, 3c, 6, 7a, 7b, 8, 9b.126 The protein product of ORF1a is polyprotein pp1a, which can be proteolytically cleaved into 11 mature non-structural proteins named nsp1-11. Similarly, the protein product of ORF1ab is pp1ab, and its 15 cleaved products are named nsp1–10 and nsp12–16.126 Over the past three years, researchers have made great advances toward understanding the pathological roles of CoV-2 accessary proteins, and the results have been summarized in a recent review.127

During the infection process, CoV-2-S serves as a key to unlocking host cells and therefore determines CoV-2 tropism and infection efficiency.27 CoV-2-S has two subunits, S1 and S2, connected by a unique protein convertase site (PPC) that does not exist in other human CoVs.128 Before binding to ACE2, CoV-2-S needs to be cleaved at the PPC site to expose its receptor binding domain that resides in the S1 subunit. Once encountering host cells, CoV-2 infects them through two different paths: the cell membrane fusion route and the endocytosis route.

In the cell membrane fusion route, transmembrane serine proteinase 2 (TMPRSS2) from the host cells cleaves S2 subunit and causes it to undergo dramatic structural change, which allows the cleaved S2 (S2’) to insert into the host cell membrane and facilitates the forming of virus-host cell fusion pores through which the CoV-2 RNA and RNA-associated nucleocapsid are released into the host cells.129

In the endocytosis route, clathrin, a triskelion-shaped scaffold protein that acts to form an endosome, is essential for virus infection.130 Once engulfed by clathrin-mediated phagocytosis, the viral particles release their RNA into host cell cytosol by forming fusion pores on endosomal membranes, a process that requires Cathepin L-mediated CoV-2-S cleavage.131,132 Of note, CoV-2 may primarily take advantage of the endocytosis route to infect CMs, because blocking Cathepin L and not TMPRSS2 activity abolished CoV-2 infection of hPSC-derived CMs.49

Due to its importance in the CoV-2 life cycle, CoV-2-S has gained attentions from many researchers and a large body of publications has shown that in addition to facilitating virus entry, CoV-2-S also has other pathological roles that govern CoV-2 virulence. In the following sections, I will focus on updating the non-infection pathological roles of CoV-2-S, with an aim of extending our knowledge about whether CoV-2 employs its spike protein to damage the cardiovascular system (Fig. 3).Fig. 3 SARS-CoV-2 spike protein (CoV-2-S) has multiple pathological roles. Besides serving as the crucial factor mediating virus entry, CoV-2-S also harms the host cells and organs in many ways. A. CoV-2-S glues neighboring cells together to form a giant cell containing multiple nuclei (Syncytium). PS: phosphatidylserine. B. CoV-2-S binds to cell surface-localized innate immune receptors to inflame tissue cells and peripheral immune cells. TLR4, Toll-like receptor 4; CLRs, C-type lectin receptors. C. CoV-2-S damages the vascular endothelial cells and activates the complement system, leading to the formation of microthrombi in small vessels. EC, endothelial cell; ECM, extracellular matrix; C3AR, Complement Component 3a Receptor; ICAM-1, intercellular adhesion molecule; vWF, von Willebrand factor; P, platelet; APC, alternative complement activation pathway. D. CoV-2-S cross links antigen presenting cells and T cells, activating a large T cell population (2%–20%) by skipping the antigen selection process. MHC II, Major histocompatibility complex class II; TCR, T cell receptor; Vβ, TCR β chain variable domain.

Fig. 3

CoV-2-S causes cell-cell fusion

A hallmark of CoV-2 infection is the formation of syncytium (plural, syncytia), a giant cell that contains multiple nuclei.133 Specifically, the presence of pneumocytes syncytia is one of the typical pathological characteristics of deceased COVID-19 patients.134 This is because CoV-2 infection can force the neighboring host cells to fuse together (Fig. 3A).

The formation of syncytia is not a unique feature of COVID-19. Under normal physiological conditions, cell-cell fusion events do happen to accomplish a specialized biological function, such as myoblast fusion during skeleton muscle growth, epithelia fusion at the time of placenta formation, and macrophages fusion during tissue remodeling.135 Phosphatidylserine (PS) represents only a small fraction of the plasma membrane phospholipid components and its distribution is asymmetric, being exclusively retained in the cytofacial leaflet of the plasma membrane under homeostasis status.136 One of the crucial steps of cell-cell fusion is PS exposure which makes the cells fusion-competent. PS exposure is enzyme facilitated process, during which PS is translocated from the cytofacial leaflet to the exofacial surface,136 and this PS translocation event is probably performed by calcium (Ca2+)-activated phospholipid scramblases, such as Transmembrane Protein 16F (TMEM16F).137

In CoV-2 infected cells, CoV-2-S awakes the normally silenced cell-fusion machinery and forces these cells into a fusion-competent status, as evidenced by a recent study by Braga et al. who reported that expressing CoV-2-S in Vero Cells (an epithelial cell line) induced sudden Ca2+ transient and externalization of PS. Additionally, the authors showed that knocking down or pharmacologically blocking TMEM16F suppressed PS exposure and blunted syncytia formation in CoV-2-S positive cells.134 In another independent study, the formation of syncytia was also observed in CMs that express CoV-2-S.123

Importantly, CoV-2-S not only flags the plasma membrane for fusion but also potently impairs the delicate internal membrane systems that are crucial for maintaining intracellular compartments.138 This notion can be inferred from two recent publications. In the work by Braga et al., the authors found that inhibiting the activity of sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) abolished CoV-2-S-induced transient Ca2+ flux, suggesting that CoV-2-S interferes with SERCA activity to dysregulate the intrinsic Ca2+ handling machinery. This observation is especially important for CMs, because CMs have specialized sarcoplasmic reticulum (SR) compartment that serves as Ca2+ reservoir, and CM beating is dependent on the synchronized movement of Ca2+ into and out of the cell, as well as between the cytosol and SR,139 where SERCA is the major ATPase that pumps Ca2+ from cytosol into SR.140 In line with the study of Braga et al., Han et al. recently reported that CoV-2 infected cardiac pacemaker cells and disrupted the normal Ca2+ cycling of these specialized CMs.117 Since SR compartment serves as a reservoir to modulate cytosol Ca2+ concentration that controls CMs beating frequency and amplitude, future studies are required to define whether CoV-2-S disrupts CM Ca2+ handling machinery by impairing the SR structure.

CoV-2-S as an alarmin to trigger innate immune response

Before binding to ACE2, CoV-2-S needs to be cleaved at the PPC site to expose its receptor binding domain that resides in the S1 subunit. After attaching to host cells, the S2 subunit facilitates virus-host cell membrane fusion and virus entry,141 and the cleaved S1 subunit can be shed into body fluid and has been detected in the urine of adult COVID-19 patients.142

The direct experimental evidence that CoV-2-S is an inflammatory alarmin comes from three independent studies all of which showed that soluble CoV-2-S1 treatment of THP1 (a human monocytic cell line) cells induced inflammatory response through Toll-like Receptor 4 (TLR4), one of the best-characterized patten recognition receptors (PRRs).143, 144, 145 TLR4 and its downstream signaling cascade consists of a series of adaptor proteins and kinases that lead to the activation of NF-kB complex, a master regulator of inflammation.146 Data from my group and other groups have shown that CoV-2-S binds to TLR4 and triggers innate immune responses both in vitro143,144 and in vivo.147 Besides TLR4, Lu et al. have identified 5 ​C-type lectin receptors as myeloid cells (e.g., macrophages) PRRs that bind CoV-2-S and initiate innate immune responses.148 These studies thus provide essential molecular evidence that CoV-2-S serves as an alarmin to active innate immune responses (Fig. 3B).

These in vitro observations are bolstered by clinical studies that characterize the immune responses triggered by COVID-19 vaccines. mRNA-based COVID-19 vaccines developed by Pfizer BioNTech (BNT162b1) and Moderna (mRNA-1273) have been widely used to reduce CoV-2 infection, and both of these two vaccines use the full-length CoV-2-S coding sequence to induce humoral and cellular immune responses.149 Since the time of these COVID-19 mRNA vaccines being authorized for emergency use, a series of clinical and translational studies have been performed to analyze the vaccination-related immune responses. As discussed in the following paragraph, data from these clinical investigations further confirm that CoV-2-S directly activates the innate immune cells.

For traditional vaccines, adjuvants are the essential components that prime the innate immune cells to produce crucial cytokines required for initiating cell (T cells) and humoral (B cells) immune responses.150 Although the current COVID-19 mRNA vaccines lack conventional vaccine adjuvants, primary immunization with BNT162B2 is sufficient to activate innate and adaptive immune responses,151,152 which are further increased by the secondary immunization. These clinical studies suggest that mRNA vaccine-encoded CoV-2-S serves as both an adjuvant molecule that activates the innate immune cells and as a pathogen antigen that switches on the adaptive immune responses. Mechanistically, the intro-muscularly injected mRNA vaccines are uptaken and expressed by infiltrated white blood cells (e.g., macrophages),153 and the secreted CoV-2-S1 and not the full-length CoV-2-S antigen is released into the bloodstream one-day post-vaccination.154 CoV-2-S1 binds to the C-type lectin receptors expressed on the macrophages surface, and this interaction leads to the activation of spleen tyrosine kinase-mediated inflammatory necrosis and the secretion of IL-1β, a pro-inflammatory cytokine that signals native T cell to differentiate into effector memory CD4+ T cell.155

In summary, CoV-2-S is a putative alarmin that can be recognized by multiple PRRs, and it is able to directly activate innate immune cells, which then synthesize and release cytokines to boost the expansion of adaptive immune cells. Although activation of the innate immune responses is essential for initiating the adaptive immune responses that are pivotal for curtailing CoV-2 infection, over-activation of the innate immune cells may lead to the formation of cytokine storm, which causes collateral damage to the internal organs and underlies the pathogenesis of many COVID-19 related diseases, such as lung and heart injury.156

CoV-2-S activates complement pathway and induces microvascular thrombosis

The complement system is an arm of innate immunity comprised of a large number of plasma proteins that react with one another to opsonize pathogens and eliminate infected host cells. Complement system activation mainly occurs through three proteolytic cascades: a) the classical, b) lectin, and c) alternative complement activation pathways (APC),157 all of which converge on the proteolytic processing and activation of C3 convertase.

Being a complicated process involving the polymerization of fibrin and the activation of platelets, blood coagulation is tightly controlled by endothelial cells which express and secret anti-coagulation factors under homeostasis conditions and switch to a pro-thrombotic status when stressed by tissue injury or pathogen invasion.158 Previous studies have confirmed the presence of cross-talks between the coagulation and complement systems,159 exemplified by the fact that coagulation factors FXa, FXIa cleave C5 and C3 to form active C5a and C3a,160 and that C5a and C3a bind to their endothelial receptors to initiate pro-inflammatory signaling events that summon more platelets to the injured sites.161

Among the numerous COVID-19 pathological stresses, microvascular thrombosis (a condition where blood clots form in small vessels) is defined as one of the primary causes of lung162 and heart19 injury. Previous studies and newly published data suggest that CoV-2 infection may activate both the complement and coagulation systems, which will lead to microvascular thrombosis if not managed properly.

Mice deficient in C3 were protected from SARS-CoV infection,163 therefore, confirming the involvement of the complement system in the pathogenesis of SARS-CoV-caused acute respiratory distress syndrome. Recently, Yu et al. found that CoV-2-S and not the counterpart of the benign coronavirus OC43 activated APC on the cell surface. Factor H, a component of the complement system, is a negative regulator of the APC and it binds to the heparan-sulfate coated on the cell surface. Because CoV-2-S is known to bind heparan-sulfate,164 and adding factor H to the medium mitigated CoV-2-S-induced complement attack in cultured erythroblast cells, the authors concluded that CoV-2-S facilitated APC activation on the cell surface by dislodging factor H from heparan-sulfate that anchored on the plasma membrane.165

In vitro experiments have shown that CoV-2-S is toxic to endothelial cells and that treating endothelial cells with soluble CoV-2-S1 increased their pro-Inflammatory and pro-thrombotic responses,166,167 probably by activating the TLR4/NF-kB pathway.122 Furthermore, CoV-2-S1 treatment also caused exuberant C3 and C5b deposition on endothelial cells that further inflames endothelial cells.167 Based on these published data, it is reasonable to hypothesize that CoV-2-S1 first coerces the endothelial cells to express pro-inflammatory adhesion molecules and pro-coagulation factors, such as intercellular adhesion molecule (ICAM-1) and von Willebrand factor (vWF), which work together to recruit and activate platelets to form blood clots (Fig. 3C). In addition to directly changing endothelial cell gene expression profiles through the TLR4/NF-kB pathway, CoV-2-S1 may also activate the complement system on the endothelial cell surface, which leads to further endothelium damage and blood clotting.

The current data all fit into a hypothesis that CoV-2 infection damages endothelial cells through CoV-2-S-caused pro-inflammatory responses; however, a crucial question has not been clearly addressed: does CoV-2-S need to engage ACE2 to harm the endothelial cells? One group of studies supports the view that CoV-2-S relies on ACE2 to injure the cultured endothelial cells, because expressing stabilized ACE2 in the endothelial cells enhanced CoV-2-S toxicity168; conversely, blocking ACE2 with ACE2-antibody largely saved the endothelial cells from CoV-2-S stress.167 In contrast with these two publications, Lei et al. recently examined the endothelial cells derived from human adult and fetal arteries, vascularized tissues and iPSC, and found that only lung endothelial cells express ACE2. Additionally, Lei et al. showed that CoV-2 did not infect iPSC-derived endothelial cells but indeed flamed these cells, probably by activating the TLR4/NF-kB pathway.122

As cytokine storm, microvascular injury is another typical pathogenesis of severe COVID-19,169 highlighting the emergency of developing therapeutic reagents to prevent or reduce this vascular etiology of COVID-19. To reach this goal, more studies are required to dissect the underlying molecular mechanisms leading to microvascular injury in COVID-19. In the past three years, multiple independent studies indicate that CoV-2-S is the primary CoV-2 viral protein that damages endothelial cells and induces microvascular thrombosis; in the future, more mechanistic studies are required to narrow down the molecular signaling pathways through which CoV-2-S exerts its toxic effects over endothelial cells.

CoV-2-S as a putative superantigen (SAg)

Over the past three years, numerous clinical studies have confirmed that dysregulated innate and adaptive immune responses are central to the pathogenesis of COVID-19.170 As aforementioned, CoV-2-S may serve as an alarmin to activate innate immune responses. Here by introducing the superantigen (SAg) concept, I will discuss the possibility of CoV-2-S being a SAg to over-activate the adaptive immune system.

T lymphocytes are one of the two arms of adaptive immune cells, and the maturation and activation of T cells require robust antigen selection processes.171 During a conventional antigen-recognizing process, the antigen needs to be captured and processed by antigen-presenting cells (e.g., dendritic cells), and the processed antigen fragments are bound by Major Histocompatibility Complex class II (MHC class II) and presented to naive T cells through T cell receptors (TCRs); the formation of MHC II-antigen-TCR complex then leads to T cells proliferation and activation.

Different from conventional antigens, a SAg does not need to be processed by antigen-presenting cells, and the intact SAg directly interacts with both class II MHC molecules and the Variable region of the T cell receptor β chain (Vβ), thus skipping the antigen selection process and quickly activates a large amount of T cells (up to 20%).172 One of the best-known SAgs is bacteria-derived staphylococcal enterotoxin B (SEB), a toxic protein that causes intense T-cell proliferation and cytotoxicity.173

COVID-19 rarely causes pneumonia in children; however, multisystem inflammatory syndrome in children (MIS-C) has been observed as another category of COVID-19-related diseases, manifesting as persistent fever and hyperinflammation in multiple organs, such as the heart, gastrointestinal tract, and kidney.174 A superantigen hypothesis has been proposed to explain the pathophysiology of MIS-C175: CoV-2-S directly interacts with TCR β chain variable domain through its putative superantigen motif (T678 to Q690), therefore activating T cells and triggering hyperactive adaptive immune responses175 (Fig. 3D).

The TCR β chain gene locus contains a cluster of 52 ​Vβ gene segments, which rearrange during T-cell development to form complete V-domain exons.171 Each SAg is specific to one or a few of the Vβ gene segments, and so a SAg can stimulate 2%–20% of the total T cells. If CoV-2-S is a SAg, the Vβ gene segments of the T cells from COVID-19 patients should be different from healthy control donors. Indeed, by analyzing the next-generation immunosequencing data derived from mild/moderate and severe COVID-19 patients, Cheng et al., found that the principal components of the TCR β-chain variable gene (TRBV) repertoires corresponding to mild/moderate COVID-19 patients clustered apart from those with severe COVID-19 symptoms. Until now, six TCR Vβ gene segments have been shown to be enriched in severe COVID-19 patients, including Vβ 5–6, Vβ 13, Vβ 14, Vβ24-1175 and Vβ11-2,176,177 and in silico analysis predicted that TCRs containing these Vβ segments interact with CoV-2-S.175,177

To test whether CoV-2-S has SAg activity in experimental systems, Amormino et al. assessed the SAg activity of the CoV-2-S in cultured Jurkat T cell line and primary CD4+ T cells, and their results showed that CoV-2-S did exhibit an intrinsic SAg-like activity in these cultured T cells.178 Although these in vitro data are at odd with the CoV-2-S/superantigen hypothesis, it is still possible that CoV-2-S synergies with other endotoxins to act as a superantigen complex. For example, CoV-2-S has been shown to interact with lipopolysaccharide (LPS),179 a bacteria-derived endotoxin. Delivering CoV-2-S itself into mice did not cause significant inflammation; however, CoV-2-S robustly increased the inflammatory effect of a low dose LPS,179,180 thus supporting the notion that CoV-2-S may combine with other molecules to behave as a SAg complex.181 In consideration that severely ill COVID-19 patients have high levels of serological markers for disrupted intestinal barrier integrity and microbial translocation,182 it is valuable to further test this CoV-2-S/LPS superantigen complex hypothesis in the near future.

Although being attractive, the CoV-2-S/superantigen hypothesis needs to be further developed, and the generation of suitable animal models is essential for reaching this goal. To understand more about whether and how the CoV-2 virus triggers superantigen effects, the audiences are encouraged to read a recently published review.181

Future directions

CoV-2 is a new zoonotic virus threatening our daily life. In the past three years, human society has been struggling to fight this virus and has developed new tools for treating COVID-19. Nevertheless, CoV-2 is rapidly evolving and new immune-evading variants are quickly emerging. Due to its essential role in infection and virus packaging, CoV-2-S is the mostly mutated antigen during CoV-2 evolution, therefore the mutations in CoV-2-S are used to define variants of concerns.183 Clearly, characterizing CoV-2-S biochemical properties is critical to define the pathogenic differences between different variants, which will provide solid foundations for developing new therapeutics against COVID-19.

Recently published data have confirmed that Omicron CoV-2 has reduced pathogenicity compared to its ancestors184, 185, 186 and pinpointed the inefficient S1/S2 cleavage as the major reason accounting for Omicron CoV-2 virulence attenuation,184,185 further highlighting the importance of studying the pathological roles of CoV-2-S in COVID-19.

CoV-2-S mRNA vaccine has been widely used to combat COVID-19. Although generally safe, one of the major adverse effects of the CoV-2-S mRNA vaccine is causing myocarditis in rare cases. A recent study compared the immune responses between individuals who developed post-vaccine myocarditis and those of healthy vaccinated control subjects, and the results showed a modest increase in cytokine production and markedly elevated levels of free (unbound by antibodies) full-length spike protein in the plasma of post-vaccine myocarditis patients, whereas this full-length spike protein was not detectible in the healthy vaccinated individuals.187 These new results raised a concern about whether CoV-2-S is the culprit that directly causes myocarditis, thus requiring further investigations to elucidate the toxicity effects of CoV-2-S in the cardiovascular context.

In summary, fully understanding the pathogenesis of COVID-19 is an urgent medical need. Since CoV-2-S plays essential roles in the pathogenesis of COVID-19, it is essential and rewarding to set up the novel in vitro and in vivo experimental platforms to define how CoV-2-S disrupts host cell structure and function, which will inform the efforts of developing safe and efficient therapeutics for blocking CoV-2 infection and reducing COVID-19 symptoms.

Submission statement

This work has not been published previously and it is not under consideration for publication elsewhere. This manuscript is approved by the author and by the responsible authorities where the work was carried out. If accepted, this work will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.

Funding

Z.L. was supported by 10.13039/100000050 NHLBI (Grant number: R01HL146810 ).

Conflict of interest

The author declares that potential competing interests do not exist.

Acknowledgements

I thank Chase W. Kessinger from Masonic Medical Research Institute for critically reviewing the manuscript and giving out constructive advice.
==== Refs
References

1 Nie QH Luo XD Zhang JZ Su Q. Current status of severe acute respiratory syndrome in China World J Gastroenterol 9 8 2003 1635 1645 10.3748/wjg.v9.i8.1635 12918094
2 Zaki AM van Boheemen S Bestebroer TM Osterhaus AD Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia N Engl J Med 367 19 2012 1814 1820 10.1056/NEJMoa1211721 23075143
3 Chan JF-W Kok K-H Zhu Z Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan Emerg Microb Infect 9 1 2020 221 236 10.1080/22221751.2020.1719902
4 Woo PCY Lau SKP Chu C-M Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia J Virol 79 2 2005 884 895 10.1128/JVI.79.2.884-895.2005 15613317
5 McIntosh K Kapikian AZ Turner HC Hartley JW Parrott RH Chanock RM. Seroepidemiologic studies of coronavirus infection in adults and children Am J Epidemiol 91 6 1970 585 592 10.1093/oxfordjournals.aje.a121171 4315625
6 Fu Y Cheng Y Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools Virol Sin 35 3 2020 266 271 10.1007/s12250-020-00207-4 32125642
7 Libby P. The heart in COVID-19: primary target or secondary bystander JACC Basic Transl Sci 5 5 2020 537 542 10.1016/j.jacbts.2020.04.001 32292847
8 Cao X. COVID-19: immunopathology and its implications for therapy Nat Rev Immunol 20 5 2020 269 270 10.1038/s41577-020-0308-3 32273594
9 Atri D Siddiqi HK Lang JP Nauffal V Morrow DA Bohula EA. COVID-19 for the cardiologist: basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies JACC Basic Transl Sci 5 5 2020 518 536 10.1016/j.jacbts.2020.04.002 32292848
10 Siordia JA. Epidemiology and clinical features of COVID-19: a review of current literature J Clin Virol 127 2020 104357 10.1016/j.jcv.2020.104357
11 Guo T Fan Y Chen M Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) JAMA Cardiol 5 7 2020 811 818 10.1001/jamacardio.2020.1017 32219356
12 Lu JQ Lu JY Wang W Clinical predictors of acute cardiac injury and normalization of troponin after hospital discharge from COVID-19 EBioMedicine 76 2022 103821 10.1016/j.ebiom.2022.103821
13 Shi S Qin M Shen B Association of cardiac injury with mortality in hospitalized patients with COVID-19 in wuhan, China JAMA Cardiol 5 7 2020 802 810 10.1001/jamacardio.2020.0950 32211816
14 Artico J Shiwani H Moon JC Myocardial involvement after hospitalization for COVID-19 complicated by troponin elevation: a prospective, multicenter, observational study Circulation 147 5 2023 364 374 10.1161/CIRCULATIONAHA.122.060632 36705028
15 Dong N Cai J Zhou Y Liu J Li F. End-stage heart failure with COVID-19: strong evidence of myocardial injury by 2019-nCoV JACC Heart Fail 8 6 2020 515 517 10.1016/j.jchf.2020.04.001 32265149
16 Kim I-C Kim JY Kim HA Han S. COVID-19-related myocarditis in a 21-year-old female patient Eur Heart J 41 19 2020 1859 10.1093/eurheartj/ehaa288 32282027
17 Huang C Wang Y Li X Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 395 10223 2020 497 506 10.1016/S0140-6736(20)30183-5 31986264
18 Babuin L Jaffe AS. Troponin: the biomarker of choice for the detection of cardiac injury CMAJ (Can Med Assoc J) 173 10 2005 1191 1202 10.1503/cmaj/051291 16275971
19 Pellegrini D Kawakami R Guagliumi G Microthrombi as a major cause of cardiac injury in COVID-19: a pathologic study Circulation 143 10 2021 1031 1042 10.1161/CIRCULATIONAHA.120.051828 33480806
20 Tavazzi G Pellegrini C Maurelli M Myocardial localization of coronavirus in COVID-19 cardiogenic shock Eur J Heart Fail 22 5 2020 911 915 10.1002/ejhf.1828 32275347
21 Teerlink JR. Neurohumoral mechanisms in heart failure: a central role for the renin-angiotensin system J Cardiovasc Pharmacol 27 Suppl 2 1996 S1 S8 10.1097/00005344-199600002-00002
22 Rahimi Z Moradi M Nasri H. A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy J Res Med Sci 19 11 2014 1090 1098 25657757
23 Tikellis C Thomas MC. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease Int J Pept 2012 2012 256294 10.1155/2012/256294
24 Grippo AJ Johnson AK. Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models Stress 12 1 2009 1 21 10.1080/10253890802046281 19116888
25 Zvonarev V. Takotsubo cardiomyopathy: medical and psychiatric aspects. Role of psychotropic medications in the treatment of adults with “broken heart” syndrome Cureus 11 7 2019 e5177 10.7759/cureus.5177
26 Scally C Abbas H Ahearn T Myocardial and systemic inflammation in acute stress-induced (Takotsubo) cardiomyopathy Circulation 139 13 2019 1581 1592 10.1161/CIRCULATIONAHA.118.037975 30586731
27 Zhou P Yang XL Wang XG A pneumonia outbreak associated with a new coronavirus of probable bat origin Nature 579 7798 2020 270 273 10.1038/s41586-020-2012-7 32015507
28 Camargo RL Bombassaro B Monfort-Pires M Plasma angiotensin II is increased in critical coronavirus disease 2019 Front Cardiovasc Med 9 2022 847809 10.3389/fcvm.2022.847809
29 Sala S Peretto G Gramegna M Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection Eur Heart J 41 19 2020 1861 1862 10.1093/eurheartj/ehaa286 32267502
30 Bone RC Balk RA Cerra FB Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American college of chest physicians/society of critical care medicine Chest 101 6 1992 1644 1655 10.1378/chest.101.6.1644 1303622
31 Land WG. The role of damage-associated molecular patterns (DAMPs) in human diseases: Part II: DAMPs as diagnostics, prognostics and therapeutics in clinical medicine Sultan Qaboos Univ Med J 15 2 2015 e157 e170 26052447
32 Newton K Dixit VM. Signaling in innate immunity and inflammation Cold Spring Harbor Perspect Biol 4 3 2012 a006049 10.1101/cshperspect.a006049
33 Soriano FG Lorigados CB Pacher P Szabó C. Effects of a potent peroxynitrite decomposition catalyst in murine models of endotoxemia and sepsis Shock 35 6 2011 560 566 10.1097/SHK.0b013e31820fe5d5 21263378
34 Tian S Xiong Y Liu H Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies Mod Pathol 33 6 2020 1007 1014 10.1038/s41379-020-0536-x 32291399
35 Fox SE Akmatbekov A Harbert JL Li G Quincy Brown J Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans Lancet Respir Med 8 7 2020 681 686 10.1016/S2213-2600(20)30243-5 32473124
36 Assimakopoulos SF Eleftheriotis G Lagadinou M SARS CoV-2-Induced viral sepsis: the role of gut barrier dysfunction Microorganisms 10 5 2022 1050 10.3390/microorganisms10051050 35630492
37 Guo YR Cao QD Hong ZS The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status Mil Med Res 7 1 2020 11 10.1186/s40779-020-00240-0 32169119
38 Parrillo JE Parker MM Natanson C Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy Ann Intern Med 113 3 1990 227 242 10.7326/0003-4819-113-3-227 2197912
39 Kakihana Y Ito T Nakahara M Yamaguchi K Yasuda T. Sepsis-induced myocardial dysfunction: pathophysiology and management J Intensive Care 4 2016 22 10.1186/s40560-016-0148-1 27011791
40 Chagnon F Bentourkia M Lecomte R Lessard M Lesur O. Endotoxin-induced heart dysfunction in rats: assessment of myocardial perfusion and permeability and the role of fluid resuscitation Crit Care Med 34 1 2006 127 133 10.1097/01.ccm.0000190622.02222.df 16374166
41 Madorin WS Rui T Sugimoto N Handa O Cepinskas G Kvietys PR. Cardiac myocytes activated by septic plasma promote neutrophil transendothelial migration: role of platelet-activating factor and the chemokines LIX and KC Circ Res 94 7 2004 944 951 10.1161/01.RES.0000124395.20249.AE 14988231
42 Liu YC Yu MM Shou ST Chai YF. Sepsis-induced cardiomyopathy: mechanisms and treatments Front Immunol 8 2017 1021 10.3389/fimmu.2017.01021 28970829
43 Caforio AL Pankuweit S Arbustini E Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases Eur Heart J 34 33 2013 2636 2648d 10.1093/eurheartj/eht210 23824828
44 Jirak P Larbig R Shomanova Z Myocardial injury in severe COVID-19 is similar to pneumonias of other origin: results from a multicentre study ESC Heart Fail 8 1 2021 37 46 10.1002/ehf2.13136 33350605
45 Weckbach LT Curta A Bieber S Myocardial inflammation and dysfunction in COVID-19–associated myocardial injury Cir Cardiovasc Imag 14 1 2021 e012220 10.1016/10.1161/CIRCIMAGING.120.011713
46 Ammirati E Lupi L Palazzini M Prevalence, characteristics, and outcomes of COVID-19–associated acute myocarditis Circulation 145 15 2022 1123 1139 10.1161/CIRCULATIONAHA.121.056817 35404682
47 Nakamura Y Katano H Nakajima N SARS-CoV-2 is localized in cardiomyocytes: a postmortem biopsy case Int J Infect Dis 111 2021 43 46 10.1016/j.ijid.2021.08.015 34384897
48 Gauchotte G Venard V Segondy M SARS-Cov-2 fulminant myocarditis: an autopsy and histopathological case study Int J Leg Med 135 2 2021 577 581 10.1007/s00414-020-02500-z
49 Bailey AL Dmytrenko O Greenberg L SARS-CoV-2 infects human engineered heart tissues and models COVID-19 myocarditis JACC Basic Transl Sci 6 4 2021 331 345 10.1016/j.jacbts.2021.01.002 33681537
50 Nishiga M Wang DW Han Y Lewis DB Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives Nat Rev Cardiol 17 9 2020 543 558 10.1038/s41569-020-0413-9 32690910
51 Damiani E Donati A Girardis M. Oxygen in the critically ill: friend or foe Curr Opin Anaesthesiol 31 2 2018 129 135 10.1097/ACO.0000000000000559 29334496
52 Huang B Miao H Yuan Y PEDF decreases cardiomyocyte edema during oxygen-glucose deprivation and recovery via inhibiting lactate accumulation and expression of AQP1 Int J Mol Med 43 5 2019 1979 1990 10.3892/ijmm.2019.4132 30864707
53 Gao C Wang F Wang Z Zhang J Yang X. Asiatic acid inhibits lactate-induced cardiomyocyte apoptosis through the regulation of the lactate signaling cascade Int J Mol Med 38 6 2016 1823 1830 10.3892/ijmm.2016.2783 27779647
54 Solaini G Baracca A Lenaz G Sgarbi G. Hypoxia and mitochondrial oxidative metabolism Biochim Biophys Acta 1797 6–7 2010 1171 1177 10.1016/j.bbabio.2010.02.011 20153717
55 Santos AL Sinha S Lindner AB. The good, the bad, and the ugly of ROS: new insights on aging and aging-related diseases from eukaryotic and prokaryotic model organisms Oxid Med Cell Longev 2018 2018 1941285 10.1155/2018/1941285
56 Choudhury M Boyett MR Morris GM. Biology of the sinus Node and its disease Arrhythmia Electrophysiol Rev 4 1 2015 28 34 10.15420/aer.2015.4.1.28
57 Santoro B Tibbs GR. The HCN gene family: molecular basis of the hyperpolarization-activated pacemaker channels Ann N Y Acad Sci 868 1999 741 764 10.1111/j.1749-6632.1999.tb11353.x 10414361
58 Feldman DS Carnes CA Abraham WT Bristow MR. Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure Nat Clin Pract Cardiovasc Med 2 9 2005 475 483 10.1038/ncpcardio0309 16265588
59 Mangoni ME Nargeot J. Properties of the hyperpolarization-activated current (I(f)) in isolated mouse sino-atrial cells Cardiovasc Res 52 1 2001 51 64 10.1016/s0008-6363(01)00370-4 11557233
60 Yatani A Okabe K Codina J Birnbaumer L Brown AM. Heart rate regulation by G proteins acting on the cardiac pacemaker channel Science 249 4973 1990 1163 1166 10.1126/science.1697697 1697697
61 Gao Y Sun Y Ercan-Sencicek AG YAP/TEAD1 complex is a default repressor of cardiac toll-like receptor genes Int J Mol Sci 22 13 2021 6649 10.3390/ijms22136649 34206257
62 Kuzmich NN Sivak KV Chubarev VN Porozov YB Savateeva-Lyubimova TN Peri F. TLR4 signaling pathway modulators as potential therapeutics in inflammation and sepsis Vaccines (Basel) 5 4 2017 34 10.3390/vaccines5040034 28976923
63 Wang Y Zhu X Yuan S TLR4/NF-κB signaling induces GSDMD-related pyroptosis in tubular cells in diabetic kidney disease Front Endocrinol 10 2019 603 10.3389/fendo.2019.00603
64 Bergsbaken T Fink SL Cookson BT. Pyroptosis: host cell death and inflammation Nat Rev Microbiol 7 2 2009 99 109 10.1038/nrmicro2070 19148178
65 Fallach R Shainberg A Avlas O Cardiomyocyte Toll-like receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia J Mol Cell Cardiol 48 6 2010 1236 1244 10.1016/j.yjmcc.2010.02.020 20211628
66 Wharram BL Fitting K Kunkel SL Remick DG Merritt SE Wiggins RC. Tissue factor expression in endothelial cell/monocyte cocultures stimulated by lipopolysaccharide and/or aggregated IgG. Mechanisms of cell:cell communication J Immunol 146 5 1991 1437 1445 1993838
67 Martin S Maruta K Burkart V Gillis S Kolb H. IL-1 and IFN-gamma increase vascular permeability Immunology 64 2 1988 301 305 3134297
68 Schumacher SM Naga Prasad SV. Tumor necrosis factor-α in heart failure: an updated review Curr Cardiol Rep 20 11 2018 117 10.1007/s11886-018-1067-7 30259192
69 Gaffen SL. An overview of IL-17 function and signaling Cytokine 43 3 2008 402 407 10.1016/j.cyto.2008.07.017 18701318
70 Bozkurt B. Activation of cytokines as a mechanism of disease progression in heart failure Ann Rheum Dis 59 suppl 1 2000 i90 i93 10.1136/ard.59.suppl_1.i90 11053097
71 Sims JE Smith DE. The IL-1 family: regulators of immunity Nat Rev Immunol 10 2 2010 89 102 10.1038/nri2691 20081871
72 Liu Z Zhao N Zhu H Circulating interleukin-1β promotes endoplasmic reticulum stress-induced myocytes apoptosis in diabetic cardiomyopathy via interleukin-1 receptor-associated kinase-2 Cardiovasc Diabetol 14 2015 125 10.1186/s12933-015-0288-y 26394923
73 El Khoury N Mathieu S Fiset C. Interleukin-1β reduces L-type Ca2+ current through protein kinase Cε activation in mouse heart J Biol Chem 289 32 2014 21896 21908 10.1074/jbc.M114.549642 24936064
74 Monnerat G Alarcón ML Vasconcellos LR Macrophage-dependent IL-1β production induces cardiac arrhythmias in diabetic mice Nat Commun 7 2016 13344 10.1038/ncomms13344
75 Buoncervello M Maccari S Ascione B Inflammatory cytokines associated with cancer growth induce mitochondria and cytoskeleton alterations in cardiomyocytes J Cell Physiol 234 11 2019 20453 20468 10.1002/jcp.28647 30982981
76 Vincent TL. IL-1 in osteoarthritis: time for a critical review of the literature. F1000Res. 2019;8:F1000 Faculty Rev-934 10.12688/f1000research.18831.1
77 Hunter CA Jones SA. IL-6 as a keystone cytokine in health and disease Nat Immunol 16 5 2015 448 457 10.1038/ni.3153 25898198
78 Zhang H Wang HY Bassel-Duby R Role of interleukin-6 in cardiac inflammation and dysfunction after burn complicated by sepsis Am J Physiol Heart Circ Physiol 292 5 2007 H2408 H2416 10.1152/ajpheart.01150.2006 17220181
79 Chen F Chen D Zhang Y Interleukin-6 deficiency attenuates angiotensin II-induced cardiac pathogenesis with increased myocyte hypertrophy Biochem Biophys Res Commun 494 3–4 2017 534 541 10.1016/j.bbrc.2017.10.119 29079193
80 Smart N Mojet MH Latchman DS Marber MS Duchen MR Heads RJ. IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes Cardiovasc Res 69 1 2006 164 177 10.1016/j.cardiores.2005.08.017 16219301
81 Yu X Kennedy RH Liu SJ. JAK2/STAT3, not ERK1/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes J Biol Chem 278 18 2003 16304 16309 10.1074/jbc.M212321200 12595539
82 Kang S Tanaka T Narazaki M Kishimoto T. Targeting interleukin-6 signaling in clinic Immunity 50 4 2019 1007 1023 10.1016/j.immuni.2019.03.026 30995492
83 Bickel M. The role of interleukin-8 in inflammation and mechanisms of regulation J Periodontol 64 5 Suppl 1993 456 460 8315568
84 Russo RC Garcia CC Teixeira MM Amaral FA. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases Expet Rev Clin Immunol 10 5 2014 593 619 10.1586/1744666X.2014.894886
85 Kukielka GL Smith CW LaRosa GJ Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo J Clin Invest 95 1 1995 89 103 10.1172/JCI117680 7814650
86 Bilusic M Heery CR Collins JM Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors J Immunother Cancer 7 1 2019 240 10.1186/s40425-019-0706-x 31488216
87 Su SA Yang D Zhu W Interleukin-17A mediates cardiomyocyte apoptosis through Stat3-iNOS pathway Biochim Biophys Acta 1863 11 2016 2784 2794 10.1016/j.bbamcr.2016.08.013 27566322
88 Langley RG Elewski BE Lebwohl M Secukinumab in plaque psoriasis--results of two phase 3 trials N Engl J Med 371 4 2014 326 338 10.1056/NEJMoa1314258 25007392
89 Bhattacharya P Thiruppathi M Elshabrawy HA Alharshawi K Kumar P Prabhakar BS. GM-CSF: an immune modulatory cytokine that can suppress autoimmunity Cytokine 75 2 2015 261 271 10.1016/j.cyto.2015.05.030 26113402
90 Forechi L Baldo MP Meyerfreund D Mill JG. Granulocyte colony-stimulating factor improves early remodeling in isoproterenol-induced cardiac injury in rats Pharmacol Rep 64 3 2012 643 649 10.1016/s1734-1140(12)70860-5 22814018
91 Okada H Takemura G Li Y Effect of a long-term treatment with a low-dose granulocyte colony-stimulating factor on post-infarction process in the heart J Cell Mol Med 12 4 2008 1272 1283 10.1111/j.1582-4934.2008.00294.x 18298650
92 Hibbert B Hayley B Beanlands RS Granulocyte colony-stimulating factor therapy for stem cell mobilization following anterior wall myocardial infarction: the CAPITAL STEM MI randomized trial CMAJ (Can Med Assoc J) 186 11 2014 E427 E434 10.1503/cmaj.140133 24934893
93 Anzai A Choi JL He S The infarcted myocardium solicits GM-CSF for the detrimental oversupply of inflammatory leukocytes J Exp Med 214 11 2017 3293 3310 10.1084/jem.20170689 28978634
94 Stock AT Hansen JA Sleeman MA McKenzie BS Wicks IP. GM-CSF primes cardiac inflammation in a mouse model of Kawasaki disease J Exp Med 213 10 2016 1983 1998 10.1084/jem.20151853 27595596
95 Mathias B Szpila BE Moore FA Efron PA Moldawer LL. A review of GM-CSF therapy in sepsis Medicine (Baltim) 94 50 2015 e2044 10.1097/MD.0000000000002044
96 Liu M Guo S Hibbert JM CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications Cytokine Growth Factor Rev 22 3 2011 121 130 10.1016/j.cytogfr.2011.06.001 21802343
97 Yuan J Liu Z Lim T CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis Circ Res 104 5 2009 628 638 10.1161/CIRCRESAHA.108.192179 19168435
98 Mayer L Sandborn WJ Stepanov Y Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study Gut 63 3 2014 442 450 10.1136/gutjnl-2012-303424 23461895
99 Sandborn WJ Colombel JF Ghosh S Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis: a randomised, placebo-controlled, phase 2b study J Crohns Colitis 10 4 2016 418 428 10.1093/ecco-jcc/jjv224 26721935
100 Deshmane SL Kremlev S Amini S Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview J Interferon Cytokine Res 29 6 2009 313 326 10.1089/jir.2008.0027 19441883
101 Kaikita K Hayasaki T Okuma T Kuziel WA Ogawa H Takeya M. Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction Am J Pathol 165 2 2004 439 447 10.1016/S0002-9440(10)63309-3 15277218
102 Dewald O Zymek P Winkelmann K CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts Circ Res 96 8 2005 881 889 10.1161/01.RES.0000163017.13772.3a 15774854
103 Yokochi S Hashimoto H Ishiwata Y An anti-inflammatory drug, propagermanium, may target GPI-anchored proteins associated with an MCP-1 receptor, CCR2 J Interferon Cytokine Res 21 6 2001 389 398 10.1089/107999001750277862 11440636
104 Trifilo MJ Bergmann CC Kuziel WA Lane TE. CC chemokine ligand 3 (CCL3) regulates CD8(+)-T-cell effector function and migration following viral infection J Virol 77 7 2003 4004 4014 10.1128/jvi.77.7.4004-4014.2003 12634360
105 Price PJ Luckow B Torres-Domínguez LE Chemokine (C-C Motif) receptor 1 is required for efficient recruitment of neutrophils during respiratory infection with modified vaccinia virus Ankara J Virol 88 18 2014 10840 10850 10.1128/JVI.01524-14 25008920
106 Gibaldi D Vilar-Pereira G Pereira IR Silva AA CCL3/Macrophage inflammatory protein-1α is dually involved in parasite persistence and induction of a TNF- and IFNγ-enriched inflammatory milieu in trypanosoma cruzi-induced chronic cardiomyopathy Front Immunol 11 2020 306 10.3389/fimmu.2020.00306 32194558
107 Ye C Brand D Zheng SG. Targeting IL-2: an unexpected effect in treating immunological diseases Signal Transduct Targeted Ther 3 2018 2 10.1038/s41392-017-0002-5
108 Sobotka PA McMannis J Fisher RI Stein DG Thomas JX. Effects of interleukin 2 on cardiac function in the isolated rat heart J Clin Invest 86 3 1990 845 850 10.1172/JCI114783 2394834
109 Conceicao C Thakur N Human S The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins PLoS Biol 18 12 2020 e3001016 10.1371/journal.pbio.3001016
110 Jackson CB Farzan M Chen B Choe H. Mechanisms of SARS-CoV-2 entry into cells Nat Rev Mol Cell Biol 23 1 2022 3 20 10.1038/s41580-021-00418-x 34611326
111 Albert CL Carmona-Rubio AE Weiss AJ Procop GG Starling RC Rodriguez ER. The enemy within: sudden-onset reversible cardiogenic shock with biopsy-proven cardiac myocyte infection by severe acute respiratory syndrome coronavirus 2 Circulation 142 19 2020 1865 1870 10.1161/CIRCULATIONAHA.120.050097 32997947
112 Bulfamante GP Perrucci GL Falleni M Evidence of SARS-CoV-2 transcriptional activity in cardiomyocytes of COVID-19 patients without clinical signs of cardiac involvement Biomedicines 8 12 2020 626 10.3390/biomedicines8120626 33352880
113 Dolhnikoff M Ferreira Ferranti J de Almeida Monteiro RA SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome Lancet Child Adolesc Health 4 10 2020 790 794 10.1016/S2352-4642(20)30257-1 32828177
114 Hanson PJ Liu-Fei F Ng C Characterization of COVID-19-associated cardiac injury: evidence for a multifactorial disease in an autopsy cohort Lab Invest 102 8 2022 814 825 10.1038/s41374-022-00783-x 35437316
115 Francis ME Goncin U Kroeker A SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney PLoS Pathog 17 7 2021 e1009705 10.1371/journal.ppat.1009705
116 Yang L Nilsson-Payant BE Han Y Cardiomyocytes recruit monocytes upon SARS-CoV-2 infection by secreting CCL2 Stem Cell Rep 16 9 2021 2274 2288 10.1016/j.stemcr.2021.07.012
117 Han Y Zhu J Yang L SARS-CoV-2 infection induces ferroptosis of sinoatrial Node pacemaker cells Circ Res 130 7 2022 963 977 10.1161/CIRCRESAHA.121.320518 35255712
118 Perez-Bermejo JA Kang S Rockwood SJ SARS-CoV-2 infection of human iPSC-derived cardiac cells reflects cytopathic features in hearts of patients with COVID-19 Sci Transl Med 13 590 2021 eabf7872 10.1126/scitranslmed.abf7872
119 Marchiano S Hsiang T-Y Khanna A SARS-CoV-2 infects human pluripotent stem cell-derived cardiomyocytes, impairing electrical and mechanical function Stem Cell Rep 16 3 2021 478 492 10.1016/j.stemcr.2021.02.008
120 Bojkova D Wagner JUG Shumliakivska M SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes Cardiovasc Res 116 14 2020 2207 2215 10.1093/cvr/cvaa267 32966582
121 Avolio E Carrabba M Milligan R The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease Clin Sci (Lond) 135 24 2021 2667 2689 10.1042/CS20210735 34807265
122 Ma Z Li X Fan RLY A human pluripotent stem cell-based model of SARS-CoV-2 infection reveals an ACE2-independent inflammatory activation of vascular endothelial cells through TLR4 Stem Cell Rep 17 3 2022 538 555 10.1016/j.stemcr.2022.01.015
123 Navaratnarajah CK Pease DR Halfmann PJ Highly efficient SARS-CoV-2 infection of human cardiomyocytes: spike protein-mediated cell fusion and its inhibition J Virol 95 24 2021 e0136821 10.1128/JVI.01368-21
124 Sharma A Garcia G Jr. Wang Y Human iPSC-derived cardiomyocytes are susceptible to SARS-CoV-2 infection Cell Rep Med 1 4 2020 100052 10.1016/j.xcrm.2020.100052
125 Yang Y Wei Z Xiong C Qian H. Direct mechanisms of SARS-CoV-2-induced cardiomyocyte damage: an update J Virol 19 1 2022 108 10.1186/s12985-022-01833-y
126 Jungreis I Sealfon R Kellis M. SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes Nat Commun 12 1 2021 2642 10.1038/s41467-021-22905-7 33976134
127 Redondo N Zaldívar-López S Garrido JJ Montoya M. SARS-CoV-2 accessory proteins in viral pathogenesis: knowns and unknowns Front Immunol 12 2021 708264 10.3389/fimmu.2021.708264
128 Walls AC Park YJ Tortorici MA Wall A McGuire AT Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein Cell 181 2 2020 281 292 10.1016/j.cell.2020.02.058 e6 32155444
129 Cai Y Zhang J Xiao T Distinct conformational states of SARS-CoV-2 spike protein Science 369 6511 2020 1586 1592 10.1126/science.abd4251 32694201
130 Bayati A Kumar R Francis V McPherson PS. SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis J Biol Chem 296 2021 100306 10.1016/j.jbc.2021.100306
131 Simmons G Gosalia DN Rennekamp AJ Reeves JD Diamond SL Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry Proc Natl Acad Sci U S A 102 33 2005 11876 11881 10.1073/pnas.0505577102 16081529
132 Zhao MM Yang WL Yang FY Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development Signal Transduct Targeted Ther 6 1 2021 134 10.1038/s41392-021-00558-8
133 Buchrieser J Dufloo J Hubert M Syncytia formation by SARS-CoV-2-infected cells EMBO J 39 23 2020 e106267 10.15252/embj.2020107405
134 Braga L Ali H Secco I Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia Nature 594 7861 2021 88 93 10.1038/s41586-021-03491-6 33827113
135 Aguilar PS Baylies MK Fleissner A Genetic basis of cell–cell fusion mechanisms Trends Genet 29 7 2013 427 437 10.1016/j.tig.2013.01.011 23453622
136 Whitlock JM Chernomordik LV. Flagging fusion: phosphatidylserine signaling in cell-cell fusion J Biol Chem 296 2021 100411 10.1016/j.jbc.2021.100411
137 Suzuki J Umeda M Sims PJ Nagata S. Calcium-dependent phospholipid scrambling by TMEM16F Nature 468 7325 2010 834 838 10.1038/nature09583 21107324
138 Alberts B Johnson A Lewis J Raff M Roberts K Walter P The compartmentalization of cells Molecular Biology of the Cell 4th edition 2002 Garland Science
139 Kho C Lee A Hajjar RJ. Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapy Nat Rev Cardiol 9 12 2012 717 733 10.1038/nrcardio.2012.145 23090087
140 Tada M Toyofuku T. SR Ca(2+)-ATPase/phospholamban in cardiomyocyte function J Card Fail 2 4 Suppl 1996 S77 S85 10.1016/s1071-9164(96)80062-5 8951564
141 Shang J Wan Y Luo C Cell entry mechanisms of SARS-CoV-2 Proc Natl Acad Sci U S A 117 21 2020 11727 11734 10.1073/pnas.2003138117 32376634
142 George S Pal AC Gagnon J Evidence for SARS-CoV-2 spike protein in the urine of COVID-19 patients Kidney 2 6 2021 924 936 10.34067/KID.0002172021
143 Zhao Y Kuang M Li J SARS-CoV-2 spike protein interacts with and activates TLR41 Cell Res 31 7 2021 818 820 10.1038/s41422-021-00495-9 33742149
144 Shirato K Kizaki T. SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via Toll-like receptor 4 signaling in murine and human macrophages Heliyon 7 2 2021 e06187 10.1016/j.heliyon.2021.e06187
145 Khan S Shafiei MS Longoria C Schoggins JW Savani RC Zaki H. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway Elife 10 2021 e68563 10.7554/eLife.68563
146 Lu YC Yeh WC Ohashi PS. LPS/TLR4 signal transduction pathway Cytokine 42 2 2008 145 151 10.1016/j.cyto.2008.01.006 18304834
147 Negron SG, Kessinger CW, Xu B, Pu WT, Lin Z. Selectively expressing SARS-CoV-2 Spike protein S1 subunit in cardiomyocytes induces cardiac hypertrophy in mice. 2021.
148 Lu Q Liu J Zhao S SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2 Immunity 54 6 2021 1304 1319 10.1016/j.immuni.2021.05.006 e9 34048708
149 Jeong D-E, McCoy M, Artiles K, et al. Assemblies-of-putative-SARS-CoV2-spike-encoding-mRNA-sequences-for-vaccines-BNT-162b2-and-mRNA-1273. 2021.
150 Pulendran B S Arunachalam P O’Hagan DT. Emerging concepts in the science of vaccine adjuvants Nat Rev Drug Discov 20 6 2021 454 475 10.1038/s41573-021-00163-y 33824489
151 Arunachalam PS Scott MKD Hagan T Systems vaccinology of the BNT162b2 mRNA vaccine in humans Nature 596 7872 2021 410 416 10.1038/s41586-021-03791-x 34252919
152 Saresella M Piancone F Marventano I Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine Front Immunol 2022 13947320 10.3389/fimmu.2022.947320
153 Li C Chen Y Zhao Y Intravenous injection of COVID-19 mRNA vaccine can induce acute myopericarditis in mouse model Clin Infect Dis 74 11 2022 1933 1950 10.1093/cid/ciab707 34406358
154 Ogata AF Cheng CA Desjardins M Circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine antigen detected in the plasma of mRNA-1273 vaccine recipients Clin Infect Dis 74 4 2022 715 718 10.1093/cid/ciab465 34015087
155 Theobald SJ Simonis A Mudler JM Spleen tyrosine kinase mediates innate and adaptive immune crosstalk in SARS-CoV-2 mRNA vaccination EMBO Mol Med 14 8 2022 e15888 10.15252/emmm.202215888
156 Paludan SR Mogensen TH. Innate immunological pathways in COVID-19 pathogenesis Sci Immunol 7 67 2022 eabm5505 10.1126/sciimmunol.abm5505
157 Ricklin D Hajishengallis G Yang K Lambris JD. Complement: a key system for immune surveillance and homeostasis Nat Immunol 11 9 2010 785 797 10.1038/ni.1923 20720586
158 van Hinsbergh VW. Endothelium--role in regulation of coagulation and inflammation Semin Immunopathol 34 1 2012 93 106 10.1007/s00281-011-0285-5 21845431
159 Rawish E Sauter M Sauter R Nording H Langer HF. Complement, inflammation and thrombosis Br J Pharmacol 178 14 2021 2892 2904 10.1111/bph.15476 33817781
160 Amara U Flierl MA Rittirsch D Molecular intercommunication between the complement and coagulation systems J Immunol 185 9 2010 5628 5636 10.4049/jimmunol.0903678 20870944
161 Kerr H Richards A. Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome Immunobiology 217 2 2012 195 203 10.1016/j.imbio.2011.07.028 21855165
162 Ackermann M Verleden SE Kuehnel M Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19 N Engl J Med 383 2 2020 120 128 10.1056/NEJMoa2015432 32437596
163 Gralinski LE Sheahan TP Morrison TE Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis mBio 9 5 2018 e01753 18 10.1128/mBio.01753-18 30301856
164 Liu L Chopra P Li X Heparan sulfate proteoglycans as attachment factor for SARS-CoV-2 ACS Cent Sci 7 6 2021 1009 1018 10.1021/acscentsci.1c00010 34235261
165 Yu J Yuan X Chen H Chaturvedi S Braunstein EM Brodsky RA. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition Blood 136 18 2020 2080 2089 10.1182/blood.2020008248 32877502
166 Panigrahi S Goswami T Ferrari B SARS-CoV-2 spike protein destabilizes microvascular homeostasis Microbiol Spectr 9 3 2021 e0073521 10.1128/Spectrum.00735-21
167 Perico L Morigi M Galbusera M SARS-CoV-2 spike protein 1 activates microvascular endothelial cells and complement system leading to platelet aggregation Front Immunol 13 2022 827146 10.3389/fimmu.2022.827146
168 Lei Y Zhang J Schiavon CR SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2 Circ Res 128 9 2021 1323 1326 10.1161/CIRCRESAHA.121.318902 33784827
169 Lowenstein CJ Solomon SD. Severe COVID-19 is a microvascular disease Circulation 142 17 2020 1609 1611 10.1161/CIRCULATIONAHA.120.050354 32877231
170 Li Q Wang Y Sun Q Immune response in COVID-19: what is next Cell Death Differ 29 6 2022 1107 1122 10.1038/s41418-022-01015-x 35581387
171 Janeway CA Jr Travers P Walport M Shlomchik MJ Principles of innate and adaptive immunity The Immune System in Health and Disease 5th edition 2001 Garland Science
172 Kotzin BL Leung DY Kappler J Marrack P. Superantigens and their potential role in human disease Adv Immunol 54 1993 99 166 10.1016/s0065-2776(08)60534-9 8397479
173 Roberts AI Blumberg RS Christ AD Brolin RE Ebert EC. Staphylococcal enterotoxin B induces potent cytotoxic activity by intraepithelial lymphocytes Immunology 101 2 2000 185 190 10.1046/j.1365-2567.2000.00088.x 11012771
174 Consiglio CR Cotugno N Sardh F The immunology of multisystem inflammatory syndrome in children with COVID-19 Cell 183 4 2020 968 981 10.1016/j.cell.2020.09.016 e7 32966765
175 Cheng MH Zhang S Porritt RA Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation Proc Natl Acad Sci U S A 117 41 2020 25254 25262 10.1073/pnas.2010722117 32989130
176 Hoste L Roels L Naesens L TIM3+ TRBV11-2 T cells and IFNγ signature in patrolling monocytes and CD16+ NK cells delineate MIS-C J Exp Med 219 2 2022 e20211381 10.1084/jem.20211381
177 Porritt RA Paschold L Rivas MN HLA class I-associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children J Clin Invest 131 10 2021 e146614 10.1172/JCI146614
178 Amormino C Tedeschi V Paldino G SARS-CoV-2 spike does not possess intrinsic superantigen-like inflammatory activity Cells 11 16 2022 2526 10.3390/cells11162526 36010602
179 Petruk G Puthia M Petrlova J SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity J Mol Cell Biol 12 12 2020 916 932 10.1093/jmcb/mjaa067 33295606
180 Puthia M Tanner L Petruk G Schmidtchen A. Experimental model of pulmonary inflammation induced by SARS-CoV-2 spike protein and endotoxin ACS Pharmacol Transl Sci 5 3 2022 141 148 10.1021/acsptsci.1c00219 35774232
181 Hamdy A Leonardi A. Superantigens and SARS-CoV-2 Pathogens 11 4 2022 390 10.3390/pathogens11040390 35456065
182 Giron LB Dweep H Yin X Plasma markers of disrupted gut permeability in severe COVID-19 patients Front Immunol 12 2021 686240 10.3389/fimmu.2021.686240
183 Hirabara SM Serdan TDA Gorjao R SARS-COV-2 variants: differences and potential of immune evasion Front Cell Infect Microbiol 11 2021 781429 10.3389/fcimb.2021.781429
184 Shuai H Chan JF Hu B Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron Nature 603 7902 2022 693 699 10.1038/s41586-022-04442-5 35062016
185 Suzuki R Yamasoba D Kimura I Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant Nature 603 7902 2022 700 705 10.1038/s41586-022-04462-1 35104835
186 Meng B Abdullahi A Ferreira IATM Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity Nature 603 7902 2022 706 714 10.1038/s41586-022-04474-x 35104837
187 Yonker LM Swank Z Bartsch YC Circulating spike protein detected in post-COVID-19 mRNA vaccine myocarditis Circulation 147 11 2023 867 876 10.1161/CIRCULATIONAHA.122.061025 36597886
